Omega Z Score
OMGA  Stock  USD 6.35 0.05 0.78% 
Omega 
Omega Z Score Analysis
Omega Therapeutics' ZScore is a simple linear, multifactor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..Current Omega Therapeutics Z Score  7.8 
Most of Omega Therapeutics' fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Omega Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
 
 
 
 

To calculate ZScore one would need to know current working capital of the company, its total assets, and liabilities, amount of latest retained earnings as well as earnings before interest and tax. ZScore can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with ZScores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a socalled 'grey area' with scores of less than 1, indicating the high probability of distress. Z Score is used widely by financial auditors, accountants, money managers, loan processers, wealth advisers, as well as day traders. In the last 25 years, many financial models that utilize z score has been proved to be successful as a predictor of corporate bankruptcy.
Compare to competition 
Based on the company's disclosures, Omega Therapeutics has a Z Score of 7.8. This is 15.56% higher than that of the Healthcare sector and 133.53% higher than that of the Biotechnology industry. The z score for all United States stocks is 10.55% higher than that of the company.
Omega Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Omega Therapeutics' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Omega Therapeutics could also be used in its relative valuation, which is a method of valuing Omega Therapeutics by comparing valuation metrics of similar companies.Omega Therapeutics is currently under evaluation in z score category among related companies.
Omega Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Omega Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Omega Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in highprofile magazines, and presentations at investor conferences help move the stock higher, increasing Omega Therapeutics' value.Security Type  Shares  Value  
Wells Fargo Company  Common Shares  118  1000  
Wells Fargo Company  Common Shares  51.0  0.0  
Wells Fargo Company  Common Shares  14.3 K  89 K  
Wells Fargo Company  Common Shares  13.2 K  150 K  
Wells Fargo Company  Common Shares  41.0  1000  
Wade G W Inc  Common Shares  10 K  54 K  
Wade G W Inc  Common Shares  10 K  38 K 
Omega Fundamentals
Return On Equity  (0.52) %  
Return On Asset  (0.28) %  
Operating Margin  (62.39) %  
Current Valuation  210.4 M  
Shares Outstanding  48.05 M  
Shares Owned by Insiders  3.69 %  
Shares Owned by Institutions  88.77 %  
Number of Shares Shorted  350.77 K  
Price to Book  2.43 X  
Price to Sales  207.50 X  
Revenue  144 K  
Gross Profit  (47.72 M)  
EBITDA  (65.98 M)  
Net Income  (68.28 M)  
Cash and Equivalents  173.66 M  
Cash per Share  3.63 X  
Total Debt  19.87 M  
Debt to Equity  0.15 %  
Current Ratio  13.46 X  
Book Value Per Share  2.79 X  
Cash Flow from Operations  (57.61 M)  
Short Ratio  12.15 X  
Earnings Per Share  (2.26) X  
Target Price  15.8  
Number of Employees  79  
Market Capitalization  307.51 M  
Total Asset  233.33 M  
Z Score  7.8  
Net Asset  233.33 M 
About Omega Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Omega Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Omega Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Omega Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Omega Therapeutics, Inc. operates as a clinicalstage biotechnology company. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. Omega Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 79 people.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Omega Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate riskadjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Suggestion Now
Portfolio SuggestionGet suggestions outside of your existing asset allocation including your own model portfolios 
All Next  Launch Module 
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Omega Therapeutics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Please check Omega Therapeutics Piotroski F Score and Omega Therapeutics Valuation analysis. Note that the Omega Therapeutics information on this page should be used as a complementary analysis to other Omega Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for Omega Stock analysis
When running Omega Therapeutics price analysis, check to measure Omega Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Omega Therapeutics is operating at the current time. Most of Omega Therapeutics' value examination focuses on studying past and present price action to predict the probability of Omega Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Omega Therapeutics' price. Additionally, you may evaluate how the addition of Omega Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio ComparatorCompare the composition, asset allocations and performance of any two portfolios in your account  Go  
Aroon OscillatorAnalyze current equity momentum using Aroon Oscillator and other momentum ratios  Go  
Fundamentals ComparisonCompare fundamentals across multiple equities to find investing opportunities  Go  
Idea AnalyzerAnalyze all characteristics, volatility and riskadjusted return of Macroaxis ideas  Go  
Insider ScreenerFind insiders across different sectors to evaluate their impact on performance  Go  
Cryptocurrency CenterBuild and monitor diversified portfolio of extremely risky digital assets and cryptocurrency  Go 
Is Omega Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Omega Therapeutics. If investors know Omega will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Omega Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization 307.5 M  Return On Assets (0.28)  Return On Equity (0.52) 
The market value of Omega Therapeutics is measured differently than its book value, which is the value of Omega that is recorded on the company's balance sheet. Investors also form their own opinion of Omega Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Omega Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Omega Therapeutics' market value can be influenced by many factors that don't directly affect Omega Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Omega Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Omega Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Omega Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.